You are here: Home » PTI Stories » National » News
Business Standard

Aurobindo Pharma gets USFDA nod for infection treatment drug

Press Trust of India  |  New Delhi 

Drug firm has received final approval from the USFDA to manufacture and market tablets, used for the treatment of patients with mild to moderate infections, in the US market.

The approval has been granted in the strengths of 250 mg and 500 mg, and the product will be launched this month, said in a BSE filing.

The approved product is generic equivalent of Pfizer Inc's tablet, it added.

Quoting IQVIA sales data, the company said, the approved product has an estimated market size of USD 132 million for the 12 months ending May 2018.

currently has a total of 337 ANDA approvals (344 final approvals including 17 from and 35 tentative approvals) from the US.

Stock of Aurobindo Pharma was trading 0.06 per cent lower at Rs 616.90 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, July 11 2018. 12:30 IST